MUC1 and colorectal adenocarcinoma: The results proved that the MUC1 peptide vaccine induced an immune response in newly diagnosed colorectal adenocarcinoma patients, with an absolute reduction rate of adenoma recurrence of 38% compared to the placebo [80].